Sebastian E Sattui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4284860/publications.pdf

Version: 2024-02-01

430442 395343 1,290 38 18 33 citations h-index g-index papers 38 38 38 2337 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Annals of Internal Medicine, 2020, 172, 819-821.	2.0	177
2	Fracture mortality: associations with epidemiology and osteoporosis treatment. Nature Reviews Endocrinology, 2014, 10, 592-602.	4.3	140
3	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	1.8	121
4	<scp>SARS</scp> â€" <scp>CoV</scp> â€2 Infection and <scp>COVID</scp> â€19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Metaâ€Analysis. Arthritis and Rheumatology, 2022, 74, 766-775.	2.9	117
5	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVIDâ€19: A Case Series. Arthritis and Rheumatology, 2020, 72, 1990-1997.	2.9	96
6	Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 145-159.	1.2	95
7	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review of Clinical Immunology, 2020, 16, 659-666.	1.3	57
8	Cryopreservation modulates the detection of regulatory T cell markers. Cytometry Part B - Clinical Cytometry, 2012, 82B, 54-58.	0.7	52
9	Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	2.9	52
10	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	2.2	40
11	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	0.9	40
12	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	2.2	38
13	Comorbidities in Patients with Crystal Diseases and Hyperuricemia. Rheumatic Disease Clinics of North America, 2014, 40, 251-278.	0.8	37
14	<i>Festina lente</i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. Annals of the Rheumatic Diseases, 2020, 79, 734-736.	0.5	35
15	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	2.2	30
16	Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis and Rheumatology, 2021, 73, 1514-1522.	2.9	28
17	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. Journal of Rheumatology, 2021, 48, 1053-1059.	1.0	22
18	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatology, The, 2021, 3, e71-e82.	2.2	18

#	Article	IF	CITATIONS
19	Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 292-298.	1.6	12
20	Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 988-995.	1.6	11
21	Localized Granulomatous with Polyangiitis (GPA): Varied Clinical Presentations and Update on Treatment. Current Allergy and Asthma Reports, 2020, 20, 56.	2.4	11
22	ANCA-Associated Vasculitis in Latin America. Journal of Clinical Rheumatology, 2022, 28, 44-51.	0.5	11
23	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	1.0	9
24	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. Seminars in Arthritis and Rheumatism, 2021, 51, 1139-1145.	1.6	8
25	The impact of COVID-19 on rheumatology trainingâ€"results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.3	7
26	Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp> â€19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. ACR Open Rheumatology, 2022, 4, 128-133.	0.9	6
27	The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemporary Clinical Trials, 2016, 50, 238-244.	0.8	5
28	Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset. ACR Open Rheumatology, 2022, 4, 300-305.	0.9	5
29	The role of immunomodulatory medications in the treatment of COVID-19. Current Opinion in Rheumatology, 2021, 33, 431-445.	2.0	4
30	Dr. Conway et al reply. Journal of Rheumatology, 2021, , jrheum.210913.	1.0	2
31	Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia. Rheumatology, 2022, 61, 4455-4464.	0.9	2
32	Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Rheumatic Disease Clinics of North America, 2019, 45, 379-398.	0.8	1
33	The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World. Journal of Rheumatology, 2021, 48, 1501-1503.	1.0	1
34	Comment on: Handgrip strength is a comorbidity marker in systemic necrotizing vasculitides and predicts the risk of fracture and serious adverse events. Rheumatology, 2021, 60, e184-e185.	0.9	0
35	Reply to †Taking a stand against the politicization of medical research: how "swinging the pendulum― poses a hazard to clinical trials, study participants, and the progress of science'. Expert Review of Clinical Immunology, 2021, 17, 105-107.	1.3	0
36	Reply. Arthritis and Rheumatology, 2021, 73, 1767-1768.	2.9	0

SEBASTIAN E SATTUI

#	Article	IF	CITATIONS
37	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	1.0	0
38	Where do we go after GiACTA?. Rheumatology, 2022, , .	0.9	0